There is no national shortage of semaglutide or tirzepatide injections in the United States in 2026. FDA lists both as resolved: tirzepatide (Mounjaro, Zepbound) on October 2, 2024, and semaglutide (Ozempic, Wegovy) on February 21, 2025. A single pharmacy can still run out of a specific dose on a given week, and one older GLP-1, liraglutide, is still on the shortage list. But the supply crisis that defined 2022 to 2024 is over.
The bigger story now is what the end of the shortage changed: who can legally compound these drugs, what cash-pay prices look like, and how to avoid getting burned by a product that was never FDA-approved.
TL;DR
- FDA-designated shortages of semaglutide and tirzepatide injections are resolved. Brand-name Wegovy, Ozempic, Zepbound and Mounjaro are available through normal channels, though individual pharmacies may still have gaps.
- Liraglutide injection is the exception: it remained on FDA’s shortage list as of the tracker’s August 2026 update, and availability varies by brand and package.
- The shortage exception that let pharmacies mass-produce copies is gone. A federal appeals court backed FDA’s decision, and compounding is now limited to documented patient-specific needs.
- Prices fell: new Medicare GLP-1 Bridge copays cap at $50 a month, and manufacturer self-pay offers have appeared in the $249 to $349 range.
- If you pay out of pocket, ask any provider exactly which product you will receive and which pharmacy fills it.
Table of Contents
- Where the FDA shortage list stands today
- Why the end of the shortage changed compounding
- Prices in 2026: cheaper, but it depends how you pay
- Where GLP-1s are used most
- Our perspective: a resolved shortage is good news with fine print
- If you want to start without insurance
- How to protect yourself in a post-shortage market
- FAQ
- Sources
Where the FDA shortage list stands today
Here is the picture as of October 2026.
| Drug | Brand names | Official status | Date resolved |
|---|---|---|---|
| Tirzepatide injection | Mounjaro, Zepbound | Resolved | October 2, 2024 (reaffirmed December 19, 2024) |
| Semaglutide injection | Ozempic, Wegovy | Resolved | February 21, 2025 |
| Liraglutide injection | Victoza, Saxenda and generics | Still listed in shortage | Not resolved |
The tirzepatide date comes from FDA’s own memo, Resolution of Tirzepatide Injection Product Shortage, which documents the December 2024 reaffirmation after the agency reviewed the decision. The semaglutide and tirzepatide dates are also summarized in this status tracker, which notes that the resolutions followed supply and demand data from Novo Nordisk and Eli Lilly.
Two details matter for readers who search for a “Wegovy shortage update” or a “Zepbound shortage update.” First, the national status is resolved for both. Second, “resolved” does not guarantee your corner pharmacy has your dose in the fridge. The RX Index tracker makes the same distinction: no national shortage, but a particular pharmacy, package or dose can be temporarily unavailable.
Back in 2024, Wegovy’s lowest strength was the last to recover. FDA data reported in August 2024 showed Wegovy 0.25 mg/0.5 mL still in limited supply while the rest had recovered. That lowest starting dose is the one a new patient needs, which is why starting-dose availability was the thing to watch. Today that is no longer flagged nationally.
What to do if your pharmacy is out
- Call the pharmacy and ask whether the exact strength can be ordered, and when.
- Ask your prescriber to send the prescription to a different licensed pharmacy rather than switching doses on your own.
- Do not substitute a different strength or drug without your prescriber’s direction. Doses are titrated for a reason, and skipping steps can bring back nausea and other side effects.
- If a gap lasts more than a couple of weeks, ask your prescriber how to restart safely. They decide whether you resume at a lower dose.
Why the end of the shortage changed compounding
During the shortage, FDA allowed pharmacies to compound copies of semaglutide and tirzepatide under a shortage exception. When the shortage ended, so did the legal basis for that.
In 2026, a federal appeals court sided with the agency. Bloomberg Law reported that FDA and the drugmakers defeated compounders in the fight over the shortage declaration. In practical terms, large-scale compounding of copies is no longer protected by the shortage exception.
FDA’s April 2026 policy statement reminds compounders that specific conditions under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act must be met to qualify for exemptions. Compounding is meant for a specific patient need that an approved product cannot meet, such as an allergy to an inactive ingredient or a dosage form not commercially manufactured. Convenience or price is not that need.
Enforcement is active. According to a law firm analysis, FDA issued 25 warning letters during the week of June 15, 2026, to telehealth companies over allegedly false or misleading claims about compounded GLP-1 products.
The compounded market did not disappear
Despite all this, compounded GLP-1s remain easy to find. A secret shopper study of 75 weight-loss clinics and medical spas in West Virginia and Oklahoma found that compounding continued after the shortages ended. The same Medscape report cites a JAMA Health Forum finding that 19% of pharmacies surveyed lacked sterile compounding licenses.
Imports are also under tighter control. FDA’s Import Alert 66-80 allows detention without physical examination of GLP-1 bulk drug substances, and the listing states that 21% of the sites evaluated did not meet current good manufacturing practice requirements.
If you are weighing a compounded product, these are the questions worth asking:
- Which pharmacy fills it, and is it licensed in your state?
- Is it a 503A pharmacy (patient-specific prescriptions) or a 503B outsourcing facility (registered with FDA)?
- Is there third-party purity testing and a certificate of analysis?
- Is it a vial you measure yourself or a pre-filled pen? Confusing milligrams, milliliters and syringe units is a documented driver of dosing errors with vials.
- What documented clinical need justifies a compounded version instead of the approved product?
For more on this, see our guides to compounded semaglutide safety and compounded tirzepatide safety. A clinician-written look at compounding and the tirzepatide versus semaglutide question is another place to read about patient safety with these products.
Prices in 2026: cheaper, but it depends how you pay
Less scarcity and more competition have pushed prices down. Brand-name GLP-1s historically cost $1,000 to $1,350 a month at retail. Negotiated agreements in late 2025 secured net prices under half of that.
Two changes matter most:
- Medicare GLP-1 Bridge. Starting July 1, 2026, eligible Medicare beneficiaries pay a copay capped at $50 a month, supported by a negotiated net price of $245 per 30-day supply, per AmeriLife’s coverage guide. Actuarial analysis describes it as a demonstration running July 1, 2026 through December 31, 2027, not a permanent formulary addition. Our guide to Medicare coverage for weight loss drugs explains who qualifies.
- Manufacturer self-pay offers. The same AmeriLife guide notes programs offering Wegovy for $249 to $349 a month for new patients. Terms change, so check the manufacturer’s current page before you decide.
If you have commercial insurance, coverage still varies by plan. Our guides to Wegovy insurance and whether insurance covers Zepbound walk through the common hurdles. If you have no coverage, see GLP-1 cost without insurance, semaglutide cost and tirzepatide cost.
Where GLP-1s are used most
Demand is not even across the country. Using 2024 prescription data, one analysis found the highest per-capita use in West Virginia (24,217 prescriptions per 100,000 residents), Kentucky (22,004) and Louisiana (20,282). Hawaii was lowest at about 5,050. Alaska saw a 21.8% rise in prescription volume, while Louisiana fell 11.6%.
That spread helps explain why local stock problems can feel different from one place to another. A medical weight loss comparison of semaglutide and tirzepatide can help you think through which drug to ask about if your first choice is hard to get locally.
Our perspective: a resolved shortage is good news with fine print
We talk with patients every week who still assume GLP-1s are scarce, and some who assume a cheap vial must be the same thing as the branded pen. Neither is quite right.
Our view is simple. Approved medication is now available, so the reason to accept a product of uncertain origin has mostly vanished. Cost was always the real barrier for people paying out of pocket, and that is where we focus: straightforward cash pricing, no membership fee, no insurance requirement, and a provider visit included. Our own pricing is on the site, and we would rather you compare it against anything else on the same terms: what exactly is the product, who dispenses it, who follows up with you.
A few things we tell every new patient:
- Ask what is in the box. Brand-name, generic or compounded is a question with a plain answer.
- Expect a real medical assessment, not a checkout page. Your history, current medications and goals decide what is right for you.
- Plan for support. Appetite changes, nausea and plateaus are normal parts of the process, and having someone to message makes people more likely to stay on track.
- Read the safety information before your first dose, not after.
The shortage ending does not make GLP-1s right for everyone. It makes the decision a medical one again, and less of a scramble.
— Bryan
If you want to start without insurance
If you are paying out of pocket and want a provider to review whether a GLP-1 fits you, Legacy Meds offers an online program with a telemedical provider assessment, free shipping, personalized plans and unlimited coaching, with no membership fees and no insurance needed. Published pricing starts from $159 per month for the semaglutide program, from $159 one-off for GLP-1 injections and from $249 one-off for GLP-1 tablets. Wegovy® Pill, Wegovy® Injection and Zepbound® Injection are also listed, without published prices. Final eligibility and treatment are decided by the provider after your intake.
How to protect yourself in a post-shortage market
Check the official status yourself. FDA’s drug shortages database is the source of truth. Social media posts and marketing pages often cite outdated shortage claims to justify compounded products.
Be wary of urgency. If a provider says supply is about to run out and you must buy now, that conflicts with the national status above.
Verify the pharmacy. Ask for the name and state license. FDA’s own warnings emphasize that compounded drugs are not reviewed for safety, effectiveness or quality before they are marketed, a point echoed in this safety overview.
Know your starting dose and your titration schedule. Pre-filled pens and tablets remove most measuring errors. If you receive vials, insist on written, step-by-step training.
Tell your prescriber about every medication you take. Anyone with a history of pancreatitis, certain thyroid cancers or pregnancy plans should discuss risks with a clinician before starting. Our GLP-1 medication safety information lists the main warnings.
Choosing between drugs. If your first-choice drug is hard to find, ask whether the other is a fit rather than switching on your own. We compare them in semaglutide vs tirzepatide.
FAQ
Are there currently any GLP-1 drug shortages in the United States?
Not for semaglutide or tirzepatide injections. FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage in February 2025. Liraglutide injection was still listed in shortage as of an August 2026 tracker update, and a specific pharmacy can still be out of a given strength.
Is Wegovy or Zepbound still in short supply?
Both are officially off the national shortage list. If your pharmacy cannot fill your dose, ask them to order it or ask your prescriber to send the prescription elsewhere. Do not change doses on your own.
Are GLP-1s going to be cheaper in 2026?
They already are for many people. Eligible Medicare beneficiaries can pay a $50 monthly copay through the GLP-1 Bridge, which runs from July 1, 2026 through the end of 2027. Some manufacturers also offer self-pay Wegovy programs in the $249 to $349 range for new patients, so check current terms.
Is compounded semaglutide or tirzepatide still legal?
Only in narrow cases. With the shortage over, compounding is meant for a specific patient need an approved product cannot meet, such as an allergy to an inactive ingredient. Mass production of copies no longer has a shortage exception to rely on.
Which state has the most GLP-1 patients?
By 2024 prescriptions per capita, West Virginia ranked highest, followed by Kentucky and Louisiana. Hawaii ranked lowest. These are per-capita rates, not total patient counts.
Sources
- GLP-1 shortage status, October 2026
- FDA: Resolution of Tirzepatide Injection Product Shortage
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- GLP-1 Shortage Tracker: FDA Status 2026
- FDA, drugmakers defeat compounders in fight over GLP-1 shortage
- FDA’s focus returns to compounding and telehealth
- Compounded GLP-1s still widespread despite shortage fix
- FDA Import Alert 66-80
- Is compounded semaglutide safe
- FDA: Ozempic, Wegovy, Mounjaro, Zepbound shortages mostly resolved
- Medicare Weight Loss Drugs: 2026 Coverage Guide
- CMS GLP-1 Bridge sets $50 copay
- GLP-1 usage by state